MENU
+Compare
YMAB
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$5.72
Change
-$0.32 (-5.30%)
Capitalization
256.19M

YMAB Y-mAbs Therapeutics Forecast, Technical & Fundamental Analysis

a developer of novel antibody therapeutics for oncology targets

Industry Biotechnology
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for YMAB with price predictions
Feb 21, 2025

YMAB sees its Stochastic Oscillator recovers from oversold territory

On February 06, 2025, the Stochastic Oscillator for YMAB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 53 instances where the indicator left the oversold zone. In of the 53 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where YMAB's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for YMAB just turned positive on January 22, 2025. Looking at past instances where YMAB's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where YMAB advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .

YMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on YMAB as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where YMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for YMAB entered a downward trend on February 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). YMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (2.978) is also within normal values, averaging (251.221).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. YMAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. YMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

YMAB is expected to report earnings to fall 27.19% to -11 cents per share on March 04

Y-mAbs Therapeutics YMAB Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.09
Q1'24
Missed
by $0.01
Q4'23
Beat
by $0.18
The last earnings report on November 08 showed earnings per share of -15 cents, missing the estimate of -15 cents. With 325.89K shares outstanding, the current market capitalization sits at 256.19M.
A.I. Advisor
published General Information

General Information

a developer of novel antibody therapeutics for oncology targets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
230 Park Avenue
Phone
+1 646 885-8505
Employees
100
Web
https://www.ymabs.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSRAX8.60-0.03
-0.35%
Fidelity Advisor Strategic Real Ret A
SVBIX29.16-0.29
-0.98%
JHancock Balanced I
LHCCX18.91-0.38
-1.97%
Lord Abbett Health Care C
FIJDX29.47-0.83
-2.74%
Fidelity Advisor Gold Z
ULPIX142.07-5.05
-3.43%
ProFunds UltraBull Inv

YMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with FATE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
-5.30%
FATE - YMAB
45%
Loosely correlated
-8.09%
RCKT - YMAB
43%
Loosely correlated
-3.68%
ARWR - YMAB
42%
Loosely correlated
-5.06%
CRSP - YMAB
41%
Loosely correlated
-5.00%
NKTX - YMAB
41%
Loosely correlated
-4.65%
More